J&J has recruited about 45,000 volunteers for a Phase 3 clinical trial of the company's COVID-19 vaccine. That number of participants will be enough to obtain the data needed to determine the efficacy and safety of the vaccine. J&J expects to receive interim Phase 3 data in late January and apply to the FDA for emergency approval of the vaccine in February.